Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial. Pfizer has terminated the development of its oral obesity candidate danuglipron after a ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company ... Pfizer previously discontinued a twice-daily version of the pill in December 2023 after patients ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing ... in late 2023 that it would abandon a twice-daily version of danuglipron that had ...

Morgan Stanley Research re-evaluated the global market for obesity ... setback for Pfizer's danuglipron, either. The company scrapped development of its twice-daily weight-loss pill in 2023 ...

In December 2023, the company stopped the development of the twice-daily version of danuglipron ... % at market open today (14 April). "Pfizer drops obesity pill development after liver injury ...